Our recent studies on the treatment of twenty-four patients with end stage acute myeloid leukemia and myeloid blast crisis of granulocytic leukemia with tiazofurin revealed that in this poor prognosis group of patients five attained complete seen in four others. The effect lasted for 3 to 10 months with intermittent drug treatment. We have demonstrated that only 50% of the patients respond; therefore, we need a predictive test to spare those patients who might not benefit. Therefore, the first Specific Aim of the proposal is to test the hypothesis that an in vitro test to predict the sensitivity of leukemic cells of patients to tiazofurin can be developed on the basis of biochemical targets. To test this hypothesis, we will elucidate the relationship between the predictive test, which would be based on the levels of TAD (thiazole-4-carboxamide adenine dinucleotide, active metabolite of tiazofurin) and the associated decrease in the GTP pools (target of tiazofurin action); and tiazofurin metabolizing enzyme activities (tiazofurin phosphorylation, NAD pyrophosphorylase and TAD phosphodiesterase). To achieve this goal the project plans to separate and enrich leukemic cells from leukemic patients and their counter parts (from healthy volunteers) and incubate in vitro with radiolabeled tiazofurin. The second Specific Aim of this project is to test the hypothesis that the regulation of tiazofurin metabolism and the extent of conversion of tiazofurin to TAD is correlated with hematologic response in refractory leukemia. To test this hypothesis blood samples will be obtained from patients undergoing tiazofurin therapy and the concentration of TAD in leukemic cells will be correlated with GTP levels and hematologic response. The activities of tiazofurin metabolizing enzymes will be determined in duplicate cell samples prepared for the predictive test. The third Specific Aim of this 5-year program is to test the hypotheses that the emergence of tiazofurin resistant leukemic cells is regulated by tiazofurin metabolism. to test this hypothesis we will elucidate the regulation of TAD by monitoring the extent of TAD synthesis by tiazofurin metabolizing enzymes, and the targets, IMP dehydrogenase activity and GTP pools in leukemic cells obtained from patients sensitive and clinically refractory to tiazofurin. This program should yield novel conceptual approaches to the treatment of human leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA051770-02
Application #
3196429
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1991-01-01
Project End
1993-12-31
Budget Start
1992-01-01
Budget End
1992-12-31
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Barchi Jr, J J; Cooney, D A; Ahluwalia, G S et al. (1996) Studies on the mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblasts. J Exp Ther Oncol 1:191-203
Gharehbaghi, K; Burgess, G S; Collart, F R et al. (1994) p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene. Leukemia 8:1257-63
Szekeres, T; Fritzer, M; Strobl, H et al. (1994) Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells. Blood 84:4316-21
Szekeres, T; Gharehbaghi, K; Fritzer, M et al. (1994) Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol 34:63-6
Gharehbaghi, K; Paull, K D; Kelley, J A et al. (1994) Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase. Int J Cancer 56:892-9
Gharehbaghi, K; Sreenath, A; Hao, Z et al. (1994) Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem Pharmacol 48:1413-9
Jayaram, H N; Zhen, W; Gharehbaghi, K (1993) Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells. Cancer Res 53:2344-8
Pillwein, K; Schuchter, K; Ressmann, G et al. (1993) Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells. Int J Cancer 55:92-5
Mandanas, R A; Leibowitz, D S; Gharehbaghi, K et al. (1993) Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 82:1838-47
Jayaram, H N; Lapis, E; Tricot, G et al. (1992) Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. Int J Cancer 51:182-8

Showing the most recent 10 out of 15 publications